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isaac cardiel7, Alfonso Berrocal8, Raquel Luque9, Ana Herrero10 & carmen Balana  1
circulating biomarkers in blood may provide an interesting alternative to risky tissue biopsies in the 
diagnosis and follow-up of glioblastoma patients. We have assessed MGMT methylation status in blood 
and tissue samples from unresected glioblastoma patients who had been included in the randomized 
GENOM-009 trial. Paired blood and tissue samples were assessed by methylation-specific PCR (MSP) 
and pyrosequencing (PYR). After establishing the minimum PYR cut-off that could yield a significant 
difference in overall survival, we assessed the sensitivity, specificity, positive predictive value and 
negative predictive value (NPV) of the analyses. Methylation could be detected in cfDNA by both 
MSP and PYR but with low concordance with results in tissue. Sensitivity was low for both methods 
(31% and 38%, respectively), while specificity was higher for MSP in blood than for PYR in plasma 
(96% vs 76%) and NPV was similar (56 vs 57%). Concordance of results in tissue by MSP and PYR was 
84.3% (P < 0.001) and correlated with outcome. We conclude that detection of cfDNA in the blood of 
glioblastoma patients can be an alternative when tumor tissue is not available but methods for the 
detection of cfDNA in blood must improve before it can replace analysis in tumor tissue.
Glioblastoma accounts for the majority of gliomas (56.6%), with an incidence rate of 3.21 cases per 100,000. It is 
the malignant glial tumor with the worst outcome1. Clinical prognostic factors are age, functional and cognitive 
status, and extent of surgery, where patients with only biopsy have the worst prognosis2,3. The standard treatment, 
established in 2005 and not modified since, consists of maximal surgical excision followed by radiation therapy 
with concomitant and adjuvant temozolomide (TMZ)4. TMZ is a cytotoxic drug that acts as an alkylating agent. 
Methylation of the promoter of O6-methylguanine DNA methyltransferase (MGMT) impairs production of the 
DNA repair enzyme, which enhances the cytotoxic effect of TMZ. MGMT methylation is thus an important pre-
dictive and prognostic factor of TMZ treatment5, and patients with unmethylated (UNMET) MGMT seem to gain 
only a marginal benefit from adding TMZ to radiation therapy. The analysis of MGMT methylation is mandatory 
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in clinical trials and is an important element in routine clinical practice when deciding between radiotherapy 
alone or combined with TMZ in elderly patients6–8.
Other molecular alterations also drive the pathogenesis and behavior of glioblastoma and may affect clinical 
outcome and the sensitivity of tumors to therapy9–13. Intense research into these alterations has led to a new 
World Health Organization (WHO) central nervous system (CNS) tumor classification that incorporates several 
molecular diagnostic markers in addition to morphological criteria14. Furthermore, for a rapid integration of 
molecular pathogenesis into clinical practice, the Consortium to Inform Molecular and Practical Approaches 
to CNS Tumor Taxonomy (cIMPACT-NOW), established in 2016, regularly updates information on molecular 
criteria and clinical outcome15.
Over the last few years, there has been a growing interest in the analysis of tumor molecular alterations in 
body fluids, a practice known as “liquid biopsy”16–18. In cell-free DNA (cfDNA), for example, investigators have 
detected point mutations, microsatellite alterations, chromosomal alterations, and hypermethylation of promoter 
sequences19–21. Liquid biopsies are of special interest in brain tumors for several reasons. Firstly, due to the dif-
ficulty in obtaining tissue from tumors located in areas that are eloquent or not easily accessible, such as the 
brain stem, liquid biopsies are a highly promising diagnostic tool. Secondly, liquid biopsies are a non-invasive 
method to monitor molecular changes in tumors throughout the evolution of the disease20,22. Finally, the prob-
lems involved in differentiating real tumor from treatment-related processes, such as radionecrosis, pseudopro-
gression, pseudoresponse and immune-related events with magnetic resonance imaging (MRI)23,24 suggest that 
liquid biopsies could be useful for monitoring treatment response and detecting recurrence. Molecular alterations 
in brain tumors have been detected in cerebrospinal fluid (CSF) and in blood (serum/plasma), includingaltera-
tions in DNA in exosomes and circulating tumor cells (CTCs), in cfDNA, and in microRNAs25,26.
Our group has a long history of analyzing cfDNA in glioblastoma, through the assessment of MGMT methyl-
ation in blood using methylation-specific PCR (MSP)27,28. However, we hypothesized that by using a more stand-
ardized and objective method, such as pyrosequencing, we could obtain more accurate results. Therefore, we used 
MSP and pyrosequencing (PYR) to analyze MGMT methylation both in tumor tissue and in paired blood samples 
from a homogeneous cohort of unresected glioblastoma patients and compared the results of the four analyses.
Results
Patients in the present study had been included in the randomized phase II trial GENOM009 (clinicaltrials.
gov NCT01102595)29. MGMT methylation status both in blood and tissue by MSP was a secondary objective in 
the trial. Of the 102 patients registered in the trial, nine withdrew before starting treatment and had no further 
follow-up, so they were not included in the outcome analyses. Ninety-three patients were randomized: 45 to 
receive TMZ and 48 to receive TMZ plus bevacizumab (BEV). Patient characteristics are summarized in Table 1.
We received 83 blood samples and 81 tissue samples from patients included in the GENOM 009 trial for the 
purpose of assessment of MGMT methylation by MSP. Of the 83 blood samples, six were too hemolyzed and 
three did not amplify correctly so we obtained results from 74 samples. After the analysis of MGMT methylation 
in blood (MSP-blood), 64 blood samples remained available for analysis by PYR. Of these 64 samples, 56 were 
able to be processed for PYR analysis in serum (PYR-serum) and 55 were able to be processed for PYR analysis in 
plasma (PYR-plasma). Analysis by MSP-blood was informative for 74 patients, while analysis by PYR-serum was 
informative for 53 patients and by PYR-plasma for 49 patients. Of the 81 tumor samples, eight did not amplify 
correctly for analysis by MSP in tumor (MSP-tumor). After MSP-tumor, 78 tumor samples were available for 
analysis by PYR. Four of the eight samples that had not amplified correctly for MSP-tumor were rescued for 
analysis by PYR in tumor (PYR-tumor). Analysis of MGMT methylation by MSP-tumor was informative for all 
73 patients, while analysis by PYR-tumor was informative for all 74 patients. Not all patients had informative 
results for all the analyses; 70 patients had results for both MSP-tumor and PYR-tumor, 50 had results for both 
MSP-tumor and MSP-blood, 33 had results for both PYR-tumor and PYR-plasma, and 39 had results for both 
PYR-tumor and PYR-serum (Fig. 1).
Correlation between MGMT methylation status by each of the analyses and patient outcome in terms of clini-
cal benefit, progression-free survival (PFS), or overall survival (OS) was only calculated for patients who had been 
randomized in the trial and who had informative results for the analysis of MGMT methylation (Fig. 1).
Cut-off points for PYR-tumor, PYR-plasma, and PYR-serum. Table 2 depicts percentages of cytosine 
methylation in tumor tissue, plasma, serum, and normal tissue for each of the five CpG sites analyzed and for 
the mean of all five, as well as the optimal and minimum cut-off points to identify differences in OS. The optimal 
cut-off points were 11.4% for PYR-tumor and 3.4% for PYR-plasma. Since the cut-off for PYR-serum (1.6%) was 
not associated with a significant difference in OS, we ruled out PYR-serum values for further analyses. Minimum 
cut-offs were 5.0% for PYR-tumor and 3.4% for PYR-plasma. This minimum cut-off was used to classify patients 
as having MGMT methylation (MET) or not having MGMT methylation (UNMET) by PYR for further analyses.
Mean values of the five CpG sites in non-tumor tissue were 2.4% for colon samples, 3.6% for brain samples, 
and 2.8% for lymphocytes, indicating that some degree of methylation can be found in normal tissue, although all 
values were under the minimum cut-off identified for glioblastoma tissue (Table 2).
MGMT methylation by MSP-tumor and PYR-tumor. MSP-tumor identified 35 patients (47.9%) as 
MET and 38 (52.1%) as UNMET, while PYR-tumor identified 39 (52.7%) as MET and 35 (47.3%) as UNMET. 
Among the 70 patients with informative results for both MSP-tumor and PYR-tumor, eight (11.4%) identi-
fied as UNMET by MSP-tumor were identified as MET by PYR-tumor; conversely, three (4.3%) identified as 
MET by MSP-tumor were identified as UNMET by PYR-tumor (p < 0.001) (Table 3). Four cases classified as 
non-evaluable by MSP were evaluable by PYR. MSP-tumor had greater sensitivity (91% vs 78%) and NPV (90% 
vs 75%) to predict PYR-tumor results than did PYR-tumor to predict MSP-tumor (Table 4).
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MGMT methylation by MSP-blood and PYR-plasma compared to MSP-tumor and PYR-tumor. 
MSP-blood identified 11 patients (14.9%) as MET and 63 (85.1%) as UNMET. PYR-plasma identified 14 (28.6%) 
as MET and 35 (71.4%) as UNMET. Of 50 patients with informative results in both MSP-tumor and MSP-blood, 
MSP-blood results were different from MSP-tumor results in 19 (38%) (p = 0.02) (Table 3). Of 33 patients with 
informative results in both PYR-tumor and PYR-plasma, results differed in 12 (36.3%) (p = 0.23). Sensitivity 
was low for both MSP-blood (31%) and PYR-plasma (38%), while specificity was higher for MSP-blood than for 
PYR-plasma (96% vs 76%) (Table 4).
MGMT methylation and prognosis. MGMT methylation by MSP-tumor correlated with clinical benefit 
(p = 0.01), PFS (p = 0.001), and OS (p = 0.001). MGMT methylation by PYR-tumor also correlated with out-
comes (p = 0.006, p = 0.001, p = 0.005, respectively). MSP-blood results were not significantly associated with 
Characteristic N = 102 N (%)




A: temozolomide 53 (52.0%)
B: temozolomide + bevacizumab 49 (48.0%)
Age, yrs
median (range) 63 (36–79)
≥50 years old 97 (95.1%)




















More than one 18 (17.6%)













Table 1. Characteristics of patients registered in the GENOM009 trial (clinicaltrials.gov NCT01102595)29. 
ECOG PS, Eastern Cooperative Oncology Group Performance Status; MMSE, Mini-Mental State Examination.
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outcome, while PYR-plasma results correlated with PFS (p = 0.002) and OS (p = 0.007) but not with clinical 
benefit (Table 5 and Figs 2 and 3).
Since four tumor samples did not amplify correctly for analysis by MSP but were able to be rescued for PYR, 
we speculated that PYR-tumor may yield more informative results than MSP-tumor. However, when we com-
pared OS in the group of patients identified as MET by either method with those identified as UNMET by both 
methods, results were not superior to those obtained with either method alone (Table 5).
Discussion
MGMT methylation status is a well-known predictive and prognostic factor in glioblastoma, and its assessment 
at the time of diagnosis is an important factor both for clinical trials and for deciding on the optimal treatment 
strategy. In the present study, we have assessed MGMT methylation in tumor tissue and in blood by MSP and 
PYR and compared the reliability of the different analyses. Although results by MSP-tumor and PYR-tumor were 
not completely identical, concordance was high (84.3%; p < 0.001) and both methods provided reliable results. 
In contrast, assessment in blood was feasible but less reliable, with a high percentage of false negatives in both 
PYR-plasma and MSP-blood and a lower level of concordance with the results in tumor tissue.
Although several methods are currently available to assess MGMT methylation, there is as yet no agreement 
about which test should be considered the “gold standard”8,30. Comparative studies often lack a previous study 
setting the optimal cut-off point for PYR related to clinical benefit31,32. To further complicate the comparison of 
results, each method can interrogate different CpG sites in the MGMT promoter region, and there is still no con-
sensus on how many CpG sites should be explored, which are most highly correlated with prognosis, and whether 
it is better to select them consecutively or randomly. In the PYR analyses in the present study, we explored CpG 
sites 74–78, which have a good correlation with the prognosis of patients newly diagnosed with glioblastoma30–34 
and which overlap almost exactly with those interrogated by MSP30,35.
In our clinical practice, we routinely use MSP to analyze MGMT methylation because it is a well-known tech-
nique, it is inexpensive when testing only a few samples, it has demonstrated sensitivity, and its results have been 
associated with outcome in clinical trials. However, MSP is a not an automatized method, making it difficult to 
standardize, and results may be influenced by tumor heterogeneity and/or a subjective interpretation. Conversely, 
PYR has been standardized and by giving a quantitative methylation percentage for each analyzed CpG, it is not 
subject to individual interpretation of results once the cut-off value has been defined. Different cut-off points 
have been recommended for PYR, with little consensus on the optimal point32,36,37, which can vary according 
to the CpG sites analyzed and which will ultimately depend on its predictive capacity. Reported cut-off values 
range from 2.7% to 35% and the number of CpG sites analyzed range from four to 6238. In the present study, we 
first defined the cut-off as the one that identified the maximal differences in OS in our patient population. In fact, 
however, differences in OS started to be seen at lower levels of methylation. Since the clinical objective behind 
determining MGMT methylation status is to identify those patients most likely to benefit from treatment with 
TMZ, we then identified the minimum cut-off that identified any differences in OS. This is in line with a recent 
pooled analysis of 4041 patients from four clinical trials, in whom MGMT methylation was analyzed by quanti-
tative MSP. Lower MGMT methylation conferred some sensitivity to TMZ, leading the authors to recommend 
Figure 1. CONSORT diagram showing patients and analyses in the study. (A) Numbers in shaded boxes 
indicate the patients included in the comparisons between the results of different analyses of MGMT 
methylation. (B) Numbers indicate patients evaluable for outcome in the GENOM 009 trial29 and with 
informative results for the MGMT methylation analyses.
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that patients in the “gray zone” of MGMT methylation should be considered as methylated in terms of treatment 
selection39.
Using the same criteria, we also determined the cut-off for PYR results in serum and in plasma. Unexpectedly, 
we found that PYR-serum values were not useful since it was impossible to set a cut-off to identify significant 
differences in OS. Serum seems to be an inadequate source of tumor derived cfDNA since it is often contaminated 
during clothing by normal nucleated cells40, which also express some degree of MGMT methylation, as we and 
others41,42 have found. In fact, in the present study, we observed a slight degree of MGMT methylation in normal 





































Percentages in PYR-tumor (N = 68), PYR-plasma (N = 45), and PYR-serum (N = 51)
Mean 18.86 7.27 6.19 19.82 8.49 7.23 18.88 9.33 7.19 19.69 8.10 6.57 13.95 8.86 7.60 18.2 8.4 6.9
Median 4.00 2.00 2.00 6.50 3.00 3.00 7.00 3.00 3.00 4.50 2.00 2.00 5.50 3.00 3.00 5.8 2.8 2.6















































Mean of 5 CpG Sites in Normal Tissuec
Colon (N = 10) Brain (N = 6) Lymphocytes (N = 5)
Mean 2.4 3.6 2.8
Median 1.6 4.9 3.0
SD 2.05 1.02 0.82
Table 2. Percentage of cytosine methylation in five CpG sites in tumor, plasma, and serum samples by 
pyrosequencing (PYR). SD, standard deviation; NC, not calculated. aThe optimal cut-off was able to identify 
maximal differences in OS. The minimum cut-off was able to identify any significant differences in OS. bp-value 
for differences in overall survival. cAll values for normal tissue were below the minimum cut-off for PYR-tumor 










84.3% <0.001MET by PYR-tumorN = 39 31 (44.3%) 8 (11.4%)
UNMET by PYR-tumor









N = 9 8 (16.0%) 1 (2.0%)
UNMET by MSP-blood









N = 7 5 (15.2%) 2 (6.1%)
UNMET by PYR-plasma
N = 26 10 (30.3%) 16 (48.5%)
Table 3. Comparison of results of MGMT methylation analysis by MSP-tumor with MSP-blood, PYR-tumor, 
and PYR-plasma. aNumbers represent the total number of patients with informative results in both tests being 
compared. bPercentages indicate the number of cases with identical results in both tests being compared. cχ2 or 
Fisher exact test.
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brain, lymphocyte, and colon tissue samples, although all values were under the minimum cut-off identified for 
glioblastoma tissue.
There was some discordance between MSP-tumor and PYR-tumor results. Eight cases identified as UNMET 
by MSP were identified as MET by PYR. This could be due to the fact that PYR can detect partial methylation 
of a given CpG that could be labelled UNMET by MSP30. In addition, three cases identified as UNMET by PYR 
were classified as MET by MSP, perhaps due to an insufficient bisulfite conversion43. Moreover, four cases deemed 
non-evaluable by MSP were evaluable by PYR, probably because less DNA is required to run PYR. These dis-
cordances led us to postulate that the two tests could complement each other, so we analyzed differences in OS 
between patients identified as MET by either test and those identified as UNMET by both tests. However, we 
found that results were similar to those obtained by each method alone. Therefore, we can conclude that both 
methods can be reliably used to identify patients as MET or UNMET and we recommend performing PYR after 
MSP only if MSP does not give an informative result and quality controls fail.
The shedding of cfDNA from tumors to fluids has been known for many years44, and multiple studies have 
shown that tumor-associated alterations can be detected in different fluids at the protein, DNA, and RNA lev-
els using diverse methods, making these liquid biopsies an easier and less invasive way to obtain information 
on the tumor. Brain tumors have not been an exception to the search for circulating biomarkers17,26,45. In the 
present study, we were able to detect methylation in cfDNA by both MSP-blood and PYR-plasma, but when we 
examined the capacity of MSP-blood and PYR-plasma to predict MGMT methylation status by the matched 
tumor assessments, concordance was relatively low, with a sensitivity of 30–40%. The specificity and PPV of 
PYR-plasma was higher than that of MSP-blood, but false negatives occurred in around 56% of cases by both 
methods. MGMT methylation in cfDNA has been studied but data on sensitivity, specificity, PPV and NPV are 
seldom reported27,46,47.
The low concordance between results obtained in tissue and plasma could be due to several factors. Firstly, 
glioblastoma tumors may not shed DNA into the circulation due to the special structure of the blood-brain bar-
rier (BBB) and the blood-brain tumor barrier (BBTB)48–50. Even though cfDNA can be detected in the blood of 
glioblastoma patients51, the release of DNA to body fluids has been related to tumor size and aggressiveness21. 
All our patients had enhancing measurable disease on the MRI (Table 1) at the time of blood sample extraction 
and enrollment in the trial. As contrast enhancement lesions on MRI are due to disruption of the BBB, this sug-
gests that these tumors would logically shed DNA, which would not be prevented by a disrupted BBB. Secondly, 
even though cfDNA is abundant in plasma, only 0.01–10% comes from tumors, while the rest is released from 
bone marrow (80–90%), or skin and the gastrointestinal tract (5–10%)21. Moreover, cfDNA in fluids is found as 
small fragments (180–200 bp) that may not contain the regions subjected to analyses of MGMT methylation. 
On the other hand, cfDNA can also be released to CSF and it seems logical that glioblastoma cfDNA would 
be more abundant in CSF, simply because CSF is in close contact with tumor cells in CNS tumors52 or because 
cfDNA could be released through areas without the BBB, such as the circumventricular organs and the choroid 
plexus53,54. In fact, diverse mutations detected in CSF could potentially be used for the diagnosis and follow-up of 
glioma52,55–59. Several studies have compared results in serum and CSF and found that sensitivity in CSF seems to 
be higher than in serum47,55. However, increased intracranial pressure can be a limitation for the routine assess-
ment of CSF in patients with intracranial hypertension because lumbar puncture carries the risk of cerebral 
herniation in these cases60. Finally, the detection of cfDNA is also limited by the sensitivity of the technique, as 
semi-quantitative PCR detects only around 1% of cfDNA. Nevertheless, if more sensitive methods for detecting 
cfDNA in fluids are developed, these limitations could be minimized in the near future61.
Comparison Parameter Point Estimates (95% CI)




























Table 4. Sensitivity, specificity, positive predictive value, (PPV), and negative predictive value (NPV) of each 
test to predict MGMT methylation status as identified by the second test.
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In summary, both PYR and MSP are reliable methods for detecting MGMT methylation in tumor tissue and 
can be useful for identifying patients likely to benefit from TMZ. MSP can be recommended for use with small 
numbers of patients, while PYR is more efficient in large numbers of cases and, moreover, can serve as a useful 
back-up when MSP results are inconclusive32,62. In contrast, both methods are imperfect for analysis in blood.
The main limitation of our study is the low number of paired tissue-blood samples that could be compared. 
Nevertheless, we are convinced that the identification of reliable circulating biomarkers can lead to major changes 
in our approach to brain tumors, making it essential to continue to search for circulating biomarkers with high 




Clinical benefit (N = 63)a 0.01
   Yes 19 (65.5) 10 (34.5)
   No 11 (32.4) 23 (67.6)
PFS (N = 67)a 0.001
   months (95% CI) 6.2 (2.3–10.0) 2.2 (1.9–2.5)
OS (N = 66)a 0.001
   months (95% CI) 12.1 (7.7–16.5) 4.9 (2.9–6.8)
MSP-blood
MET UNMET p
Clinical benefit (N = 67)a 0.17
   Yes 7 (21.9) 25 (78.1)
   No 3 (8.6) 32 (91.4)
PFS (N = 70)a 0.71
   months (95% CI) 4.8 (3.3–6.2) 2.8 (0.3–5.2)
OS (N = 71)a 0.92
   months (95% CI) 8.8 (3.9–13.6) 9.0 (6.1–11.9)
PYR-tumor
MET UNMET p
Clinical benefit (N = 65)a 0.006
   Yes 21 (72.4) 8 (27.6)
   No 8 (27.6) 23 (63.9)
PFS (N = 68)a 0.001
   months (95% CI) 4.8 (1.8–7.9) 2.2 (1.9–2.5)
OS (N = 67)a 0.005
   months (95% CI) 9.6 (7.0–12.1) 4.9 (2.3–7.4)
PYR-plasma
MET UNMET p
Clinical benefit (N = 43)a 0.31
   Yes 7 (33.3) 14 (66.7)
   No 4 (18.2) 18 (81.8)
PFS (N = 45)a 0.002
   months (95% CI) 9 (1.7–16.2) 2.8 (1.4–4.1)
OS (N = 45)a 0.007
   months (95% CI) 13.4 (0–41.3) 8.0 (5.5–10.4)
PYR-tumor + MSP-tumor
MET by either test UNMET by both tests
PFS (N = 64)a 0.01
   months (95% CI) 4.6 (2.7–6.6) 2.3 (1.8–2.6)
OS (N = 63)a 0.004
   months (95% CI) 9.6 (6.2–12.9) 4.5 (2.5–6.5)
Table 5. Clinical benefit, progression-free survival (PFS), and overall survival (OS) according to MGMT 
methylation status by MSP-tumor, MSP-blood, PYR-tumor, PYR-plasma, and MSP-tumor plus PYR-
tumor. aClinical benefit, PFS, and OS were analyzed only for patients with informative results in the MGMT 
methylation analysis. Clinical benefit was analyzed only in patients evaluable for response in the clinical trial. 
PFS and OS were analyzed for patients included in the trial.
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Methods
Patients and samples. Patients proceeded from the GENOM 009 trial29, in which unresected glioblas-
toma patients were randomized to add or not bevacizumab to two cycles of TMZ before radiation therapy with 
concomitant and adjuvant TMZ. Overall response rate, PFS and OS were primary endpoints of the trial. Results 
showed a non-significant trend towards improvement in PFS and OS for those patients treated with bevaci-
zumab. A secondary endpoint was the study of MGMT methylation status in blood as compared with tissue in 
these patients. Before patient inclusion, formalin-fixed paraffin-embedded (FFPE) tumor tissue blocks and paired 
blood samples were obtained from patients and sent to our center for assessing the methylation status of MGMT.
In addition, we obtained 21 samples of non-tumor tissue proceeding from normal brain (6), lymphocytes (5), 
and colon (10). MGMT methylation status in these samples was analyzed by PYR.
Written informed consent was obtained from all patients before registration, both for participation in the trial 
and for molecular tests. The study was approved by the Ethics Committee of the Hospital Germans Trias i Pujol, 
Badalona, Spain and by the Ethics Committees of each of the participating hospitals. All research was performed 
in accordance with relevant guidelines/regulations.
DNA extraction from tissue and serum/plasma samples. Genomic DNA was extracted from FFPE 
tissue after macrodissection was performed to assure more than 80% of tumor cells. The material was depa-
raffinated and DNA obtained using the QIAamp® DNA micro kit (Qiagen, Hilden, Germany). Venous blood 
(10 mL) was drawn from each patient into Vacutainer tubes containing SST (serum-separating tube) gel and clot 
activator (Becton Dickinson, NJ, USA), and for plasma in Vacutainer tubes containing k2E (EDTA). Serum and 
plasma were isolated after centrifugation at 2,500 rpm for 10 min at room temperature and were stored at −20 °C 
until analysis. The QIAmp® Blood Mini-Kit (Qiagen) was used to obtain DNA according to the manufacturer’s 
instructions.
DNA bisulfite conversion. DNA methylation in CpG island of MGMT (Genbank accession number 
NG_052673.1) was determined using two different methods, MSP and PYR. The first step in both methods was 
Figure 2. Progression-free survival (PFS) according to the results of the MGMT methylation analyses by (A) 
MSP-tumor, (B) PYR-tumor, (C) MSP-blood, and (D) PYR-plasma. Solid lines indicate methylated MGMT 
(MET); broken lines indicate unmethylated MGMT (UNMET).
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DNA bisulfite conversion. The bisulfite treatment converts unmethylated – but not methylated – cytosines, to 
uracil. Briefly, a total of 250 ng of genomic DNA was modified using EZ DNA Methylation-Gold ™ kit (Zymo 
Research, Ecogen, Madrid), following the manufacturer’s instructions, and recovered in a final volume of 20 μl.
MGMT methylation assessment by MSP. Bisulfite-converted DNA (2 μl) was amplified using specific 
primers (previously described for CpG sites 74–7863) for methylated and unmethylated DNA independently, 
using HotStart®Plus DNA polymerase (Qiagen, Izasa, Spain) and following the manufacturer’s instructions. 
Cycling conditions were 5 min 95 °C, followed by 42 cycles of (30′′ 95 °C, 30′′ 59 °C, 30′′ 72 °C) and 5 min at 
72 °C. PCR reactions (15 μl) were analyzed on a 2% agarose gel stained with ethidium bromide or Syber Safe. 
Commercial methylated DNA and unmethylated DNA (Zymo Research, Ecogen, Spain) served as positive con-
trols for methylated and unmethylated PCR reactions.
A sample was considered methylated when a band was observed in PCR (in duplicate) with methylated prim-
ers. When no band was observed in either tube the sample was assessed as “not evaluable”. When both duplicates 
gave different results, the test was repeated for that sample in triplicate.
MGMT methylation assessment by PYR. Bisulfite-converted DNA (2 μl) was used to amplify the 
MGMT promoter with the primers provided by the Pyromark®Q24 CpG MGMT kit. A PCR was set up with the 
reactives and conditions given by the PyroMark®PCR kit. The same CpG sites (74 to 78) analyzed by MSP were 
analyzed by PYR. Briefly, PCR conditions for tissue DNA were 5 min 95 °C, followed by 45 cycles of (20′′ 95 °C, 
30′′ 53 °C, 20′′ 72 °C) and 5 min at 72 °C. In plasma and serum, the number of cycles was increased to 50. PCR 
products (10 μl) were attached to Streptavidina Sepharose perls (GE Healthcare, Buckinghamshire, UK) and the 
template strands were purified in the Pyromark Q24 Vaccum Workstation. The purified templates were incubated 
for 20 min with the sequencing primer provided by the kit and run in the instrument Qiagen Pyromark Q24 
System with the reactives of Pyromark Gold Q24 Reagents. All the steps were followed according to the Pyromark 
Q24 user manual. Sequencing conditions and analysis of results were performed with the Pyromark Q24 sofware 
2.0.8. Commercial unmethylated DNA was used to calculate baseline (n = 13).
In case of discordant results between PYR and MSP, MSP was repeated to confirm the discordance.
Figure 3. Overall survival (OS) according to the results of the MGMT methylation analysis by (A) MSP-tumor, 
(B) PYR-tumor, (C) MSP-blood, and (D) PYR-plasma. Solid lines indicate methylated MGMT (MET); broken 
lines indicate unmethylated MGMT (UNMET).
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Determination of cut-off points for PYR-tumor, PYR-plasma, and PYR-serum results. PYR 
results were delivered as a percentage of cytosine methylation for each CpG site assessed in tissue, plasma, and 
serum. We created a new variable using the overall mean of all five CpG sites (Table 2). We calculated the cut-off 
that yielded maximal differences in OS for each CpG and for the mean (optimal cut-off point) for PYR-tumor, 
PYR-plasma, and PYR-serum. However, despite having identified the optimal cut-off point for maximal differ-
ences in OS, we reasoned that many patients with MGMT methylation status below that cut-off could still benefit 
from treatment because of a certain degree of methylation. We therefore identified the minimum cut-off point for 
the mean of all five CpG sites that yielded a significant difference in OS. This cut-off was used for further analyses. 
If the value was higher than the cut-off, a sample was classified as MET; if it was equal to or lower than the cut-off, 
a sample was classified as UNMET. All cut-off points were calculated with the Maximally Selected Rank Statistics 
(Maxstat package of R, version 1.1.442) and confirmed with the Kaplan-Meier method and log-rank test.
Statistical analyses. The epiR package of R was used to calculate the sensitivity, specificity, PPV, and NPV 
of the different analyses to predict MGMT methylation status as assessed by other analyses. Since in this case, 
none of the analyses could be considered the established gold standard against which to compare the others, 
we performed bilateral comparisons of PYR-tumor vs MSP-tumor, MSP-tumor vs PYR-tumor, PYR-plasma vs 
PYR-tumor, and MSP-blood vs MSP-tumor.
Categorical variables were compared with the χ2 test or the Fisher’s exact test. All patients who started treat-
ment were included in the analyses. Response to neoadjuvant therapy was evaluated by RANO criteria, after two 
cycles of therapy and before radiation therapy. For the purpose of analysis, responses were grouped as clinical 
benefit (stable disease, partial response, or complete response) and no clinical benefit (progression)64. PFS was 
defined as the time from inclusion to the first documented progression or death from any cause, while OS was 
defined as the time from inclusion to death from any cause. Patients who were still progression-free or alive at the 
date of last contact were censored. Median PFS and OS were calculated with the Kaplan-Meier method and com-
pared using the log-rank test. All statistical tests were two-sided and significance was set at 0.05. These analyses 
were performed with SPSS v24.0 (IBM).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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